BioSpace News Archive

Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that it has fully repaid its 2.75% convertible bonds, which were due on December 23, 2022, with an outstanding nominal amount of CHF 113.8 million.

Centogene N.V. announced that its management team, including Chief Executive Officer Kim Stratton, will be attending the 41st Annual J.P. Morgan Healthcare Meeting, on January 9-12, 2023, in San Francisco, U.S.

Biomica Ltd. and a subsidiary of Evogene Ltd., announced it will be in attendance at the Healthcare Week taking place together with the J.P. Morgan Healthcare Conference in San Francisco.

Pfizer Inc. announced that the U.S. Food and Drug Administration accepted for review a Biologics License Application for its investigational pentavalent meningococcal vaccine candidate.

Aptose Biosciences Inc. announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate at the upcoming Biotech Showcase™ 2023 Conference on Tuesday, January 10th, 2023, at 10:00 a.m. PST in San Francisco, CA.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. announced that updated NXC-201 clinical data has been selected to be presented at the upcoming European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting to be held in Rotterdam, Netherlands February 9-11, 2023.

Acasti Pharma Inc., a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces that the preliminary topline results of the pharmacokinetic bridging study for GTX-102 met all outcome measures.

Opus Genetics announced it has acquired the rights to two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases from Iveric Bio. Opus will develop the novel gene therapy candidates to address bestrophin-1 (BEST1)-related inherited retinal diseases and rhodopsin-mediated autosomal dominant retinitis pigmentosa, respectively.

China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced the launch of N95 medical protective mask.

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers.